Value
9.0/10data confidence 33%| Component | Sub-score |
|---|---|
| Analyst target | 9.0 |
- ▸Attractively valued
AKTS · Why this verdict
Why Aktis Oncology (AKTS) is rated SELL
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictSELL
Overall score5.8/10
ConfidenceMEDIUM
MacroNEUTRAL
TrendMatrix Research · core thesis
Engine thesis — one sentence
Aktis Oncology is a pre-profit biotech with 95.9% upside to the analyst target and 111% YoY revenue growth, but quality is below the 4.0 floor, the stock is 53% off its high, and short interest is 27%.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
The quality score is 3.4, below the 4.0 floor, with gross margin and net margin components both at 0.0. Quality | Quality score recovers above 4.0 as revenue scales toward profitability. | →Stable |
| CounterMargin metrics are not meaningful for a clinical-stage biotech, so a low quality score may reflect its stage and not its prospects. | ||
The $15.93 price sits 95.9% below the $31.21 analyst target, with 12.1% downside to the stop for a reward-to-risk of 7.91. Estimated upside | Price moves toward the analyst target as clinical milestones are reached. | →Stable |
| CounterBiotech analyst targets rest on binary trial outcomes, and a single failure in the lead candidate could void the target. | ||
Value depends on one lead product candidate, [225Ac]Ac-AKY-1189, flagged as a high-severity concentration risk. Bear case | Clinical data on the lead candidate is positive and supports further development funding. | ↑Improving |
| CounterA radiopharmaceutical pipeline with one lead asset has no diversification, so a safety or efficacy setback would hit the whole valuation. | ||
EPS missed estimates in 3 of the last 4 reported quarters, including -0.44 versus -0.43 in August 2026, and earnings are due in 11 days. Avg surprise pct | Quarterly loss per share narrows to better than -0.40. | →Stable |
| CounterSmall misses on losses (-0.44 versus -0.43) are close to estimates and may not signal a real change in cash burn. | ||
Short interest is 27% and implied volatility is 167% after a 53% drawdown from the 52-week high, showing strong bearish positioning. Key risks | Short interest falls below 20% as the price stabilizes. | ↑Improving |
| CounterVery high short interest can fuel a sharp squeeze on positive trial news, and rising on-balance volume suggests accumulation. | ||
The quality score is 3.4, below the 4.0 floor, with gross margin and net margin components both at 0.0.
→StableQuality
- Expectation
- Quality score recovers above 4.0 as revenue scales toward profitability.
CounterMargin metrics are not meaningful for a clinical-stage biotech, so a low quality score may reflect its stage and not its prospects.
The $15.93 price sits 95.9% below the $31.21 analyst target, with 12.1% downside to the stop for a reward-to-risk of 7.91.
→StableEstimated upside
- Expectation
- Price moves toward the analyst target as clinical milestones are reached.
CounterBiotech analyst targets rest on binary trial outcomes, and a single failure in the lead candidate could void the target.
Value depends on one lead product candidate, [225Ac]Ac-AKY-1189, flagged as a high-severity concentration risk.
↑ImprovingBear case
- Expectation
- Clinical data on the lead candidate is positive and supports further development funding.
CounterA radiopharmaceutical pipeline with one lead asset has no diversification, so a safety or efficacy setback would hit the whole valuation.
EPS missed estimates in 3 of the last 4 reported quarters, including -0.44 versus -0.43 in August 2026, and earnings are due in 11 days.
→StableAvg surprise pct
- Expectation
- Quarterly loss per share narrows to better than -0.40.
CounterSmall misses on losses (-0.44 versus -0.43) are close to estimates and may not signal a real change in cash burn.
Short interest is 27% and implied volatility is 167% after a 53% drawdown from the 52-week high, showing strong bearish positioning.
↑ImprovingKey risks
- Expectation
- Short interest falls below 20% as the price stabilizes.
CounterVery high short interest can fuel a sharp squeeze on positive trial news, and rising on-balance volume suggests accumulation.
Per-dimension breakdown
Quality
3.4/10data confidence 71%| Component | Sub-score |
|---|---|
| Gross margin | 0.0 |
| Net margin | 0.0 |
| Current ratio | 5.0 |
| Moat | 6.5 |
| Piotroski F | 5.6 |
Growth
10.0/10data confidence 33%| Component | Sub-score |
|---|---|
| Rev growth | 10.0 |
- ▸Strong growth: 111% YoY
Momentum
2.8/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 3.5 |
| MACD | 7.8 |
| OBV | 1.0 |
| MA position | 1.5 |
| Volume | 0.0 |
- ▸Volume distribution (falling OBV)
- ▸Below 200-MA, MA slope flat
Sentiment
6.6/10data confidence 100%| Component | Sub-score |
|---|---|
| Analyst rating | 5.0 |
| Price target | 10.0 |
| erm sentiment | 5.0 |
- ▸Analyst upside: 147%
Insider
3.8/10data confidence 75%| Component | Sub-score |
|---|---|
| materiality | 4.5 |
| insider conviction | 2.0 |
| holder change | 5.0 |
- ▸Modest insider selling — $258,621 (0.032% of mkt cap)
Peer rank
5.1/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 0.3 |
| quality rank | 5.0 |
| growth rank | 8.6 |
- ▸Industry growth leader
Technical
5.8/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 9.3 |
| support resistance | 8.7 |
| 52w position | 0.0 |
| gap | 5.0 |
Risk (lower is worse)
3.6/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 0.0 |
| days to cover | 1.7 |
| volatility | 0.0 |
| put call | 10.0 |
| implied vol | 0.0 |
| debt equity | 9.9 |
- ▸High short interest: 27%
- ▸High IV: 159%
- ▸Concentration risks: 1 HIGH (10-K Item 1A — sized via position_sizing, validated via buy_confidence)
Catalyst
2.8/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 1.1 |
| earnings timing | 5.0 |
| surprise avg | 0.0 |
- ▸Earnings concerns: 1B/2M
- ▸Earnings in 9 days
How the verdict was assembled
Engine trigger
Quality below minimum threshold.
Engine technical detail
verdict_path:
L1:HARD_BLOCK:QUALITY_FLOORPassed (5)
- ASYMMETRY:8.2>=1.5
- INSIDER:OK
- NEWS_EVENTS:NONE_RECENT
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (2)
- MOMENTUM:2.8<4.5
- DEATH_CROSS:HARD_BLOCK
Warning (2)
- 8K_CSUITE_CHANGE:5.02 (officer departure/appointment)
- EARNINGS_PROXIMITY:9d<=14d (soft)
Reward-to-Risk
8.18
Upside
+114.9%
Downside
14.0%
Sizing output
AVOID
Setup— — No clear chart pattern; technical signals are mixed
EdgeInst Constrain — Small cap ($0.8B) below institutional reach
SuitabilitySpeculative — Drawdown -58% (>40% off 52w high), Binary industry: Biotechnology
Investment implication
The SELL_IF_HOLDING verdict reflects the MOMENTUM gate's 2.8<4.5 outcome against Growth at 10.0 and asymmetric R:R of 8.18.
The strongest dimensions are Growth at 10.0, Value at 9.0, and Sentiment at 6.6; the weakest are Catalyst at 2.8, Momentum at 2.8, and Quality at 3.4. The V9 engine flagged 2 failed gates with 2 warnings, producing an asymmetric reward-to-risk of 8.18 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Large Analyst Upside
Trip ifAnalyst target falls below $22, cutting upside to less than 40% from current 95.9%.
- P2Single Lead Asset Concentration
Trip ifShare price falls below $10 after a clinical readout on the lead candidate, a drop of more than 37%.
- P3Quality Below Floor
Trip ifQuality score stays below 3.0 for 2 consecutive quarterly updates.
- P4Earnings Misses And Losses
Trip ifEPS surprise stays below -10% for 2 consecutive quarters.
- P5High Short Interest And Drawdown
Trip ifShort interest rises above 35% from current 27%.